Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Journal of Cancer Research and Clinical Oncology
Erschienen in: Journal of Cancer Research and Clinical Oncology 10/2010

01.10.2010 | Original Paper

Anti-mitogenic and apoptotic effects of 5-HT1B receptor antagonist on HT29 colorectal cancer cell line

verfasst von: Ramin Ataee, Soheila Ajdary, Mohammadreza Zarrindast, Mehdi Rezayat, Mohammad Reza Hayatbakhsh

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 10/2010

Einloggen, um Zugang zu erhalten

Abstract

Purpose

There is lack of evidence about impact of 5-HT receptors on colorectal cancers. The current study was designed to investigate the role of serotonin and its receptors in colorectal cancer cell line and tissues.

Methods

In cell cultures, we investigated the effects of 5-HT and 5-HT1A,1B,1D agonists and antagonists on proliferation of HT29 cells. We also tested apoptosis for the receptor antagonists. The expression of 5-HT1A,B,D receptor subtypes was examined by immunohistochemistry and western blotting.

Results

Our data indicated that 5-HT1B receptor was fully expressed in HT29 cell line and tumor tissues. MTT proliferation assay also revealed that serotonin and CP93129 dihydrochloride, a selective 5-HT1B receptor agonist, stimulated growth of HT29 cells. Further, SB224289 hydrochloride (that is a selective 5-HT1B receptor antagonist) had anti-proliferative and apoptotic effects on HT29 cells.

Conclusions

The findings of this study provide evidence for the potential role of 5-HT1B receptor in colorectal cancer. Further investigation is required to explore the effect of receptor antagonists on the prevention, prognosis and treatment of patients with colorectal cancer.
Literatur
Banes AK, Shaw SM, Tawfik A, Patel BP, Ogbi S, Fulton D, Marrero MB (2005) Activation of the JAK/STAT pathway in vascular smooth muscle by serotonin. Am J Physiol Cell Physiol 288:C805–C812CrossRefPubMed
Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein–dye binding. Anal Biochem 72:248–254CrossRefPubMed
Cattaneo MG, Codignola A, Vicentini LM, Clementi F, Sher E (1993) Nicotine stimulates a serotonergic autocrine loop in human small-cell lung carcinoma. Cancer Res 53:5566–5568PubMed
Cattaneo MG, Fesce R, Vicentini LM (1995) Mitogenic effect of serotonin in human small cell lung carcinoma cells via both 5-HT1A and 5-HT1D receptors. Eur J Pharmacol 291:209–211CrossRefPubMed
Dizeyi N, Bjartell A, Nilsson E, Hansson J, Gadaleanu V, Cross N, Abrahamsson PA (2004) Expression of serotonin receptors and role of serotonin in human prostate cancer tissue and cell lines. Prostate 59:328–336CrossRefPubMed
El-Salhy M (2005) Triple treatment with octreotide, galanin and serotonin is a promising therapy for colorectal cancer. Curr Pharm Des 11:2107–2117CrossRefPubMed
El-Salhy M, Norrgard O, Bostrom A (1998) Low levels of colonic somatostatin and galanin in patients with colon carcinoma. GI Cancer 2:221–225
El-Salhy M, Sitohy B, Norrgard O (2003) Triple therapy with octreotide, galanin, and serotonin reduces the size and blood vessel density and increases apoptosis of a rat colon carcinoma. Regul Pept 111:145–152CrossRefPubMed
El-Salhy M, Hilding L, Royson H, Tjomsland V (2005) Comparison between triple therapy with octreotide, galanin and serotonin vs. irinotecan or oxaliplatin in combination with 5-fluorouracil/leukovorin in human colon cancer. Int J Oncol 27:687–691PubMed
Hilakivi-Clarke L, Wright A, Lippman ME (1993) DMBA-induced mammary tumor growth in rats exhibiting increased or decreased ability to cope with stress due to early postnatal handling or antidepressant treatment. Physiol Behav 54:229–236CrossRefPubMed
Hill DJ (1991) Neuropeptides and cell proliferation. In: Daniel EE (ed) Neuropeptides function in gastrointestinal tract. CRC Press, Boca Raton, pp 479–490
Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, Saxena PR, Humphrey PPA (1994) VII. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev 46:157–203PubMed
Huerta S, Goulet EJ, Livingston EH (2006) Colon cancer and apoptosis. Am J Surg 191:517–526CrossRefPubMed
Ishizuka J, Beauchamp RD, Townsend CM Jr, Greeley GH Jr, Thompson JC (1992) Receptor-mediated autocrine growth-stimulatory effect of 5-hydroxytryptamine on cultured human pancreatic carcinoid cells. J Cell Physiol 150:1–7CrossRefPubMed
Launay JM, Birraux G, Bondoux D, Callebert J, Choi DS, Loric S, Maroteaux L (1996) Ras involvement in signal transduction by the serotonin 5-HT2B receptor. J Biol Chem 271:3141–3147CrossRefPubMed
Mastrangelo L, Cassidy A, Mulholland F, Wang W, Bao Y (2008) Serotonin receptors, novel targets of sulforaphane identified by proteomic analysis in CaCO2 cells. Cancer Res 68:5487–5491CrossRefPubMed
Menegola E, Broccia ML, Di Renzo F, Massa V, Giavini E (2004) Effects of excess and deprivation of serotonin on in vitro neuronal differentiation. In Vitro Cell Dev Biol Anim 40:52–56CrossRefPubMed
Oosterbosch L, von der Ohe M, Valdovinos MA, Kost LJ, Phillips SF, Camilleri M (1993) Effects of serotonin on rat ileocolonic transit and fluid transfer in vivo: possible mechanisms of action. Gut 34:794–798CrossRefPubMed
Pantaleo MA, Palassini E, Labianca R, Biasco G (2006) Targeted therapy in colorectal cancer: do we know enough? Dig Liver Dis 38:71–77PubMed
Pezzella G, Moslinger-Gehmayr R, Contu A (2001) Treatment of depression in patients with breast cancer: a comparison between paroxetine and amitriptyline. Breast Cancer Res Treat 70:1–10CrossRefPubMed
Pourgholami MH, Akhter J, Wang L, Lu Y, Morris DL (2005) Antitumor activity of albendazole against the human colorectal cancer cell line HT-29: in vitro and in a xenograft model of peritoneal carcinomatosis. Cancer Chemother Pharmacol 55:425–432CrossRefPubMed
Roth BL (1994) Multiple serotonin receptors: clinical and experimental aspects. Ann Clin Psychiatry Off J Am Acad Clin Psychiatr 6:67–78
Sharpe CR, Collet JP, Belzile E, Hanley JA, Boivin JF (2002) The effects of tricyclic antidepressants on breast cancer risk. Br J Cancer 86:92–97CrossRefPubMed
Siddiqui EJ, Thompson CS, Mikhailidis DP, Mumtaz FH (2005) The role of serotonin in tumour growth (review). Oncol Rep 14:1593–1597PubMed
Siddiqui EJ, Shabbir MA, Mikhailidis DP, Mumtaz FH, Thompson CS (2006) The effect of serotonin and serotonin antagonists on bladder cancer cell proliferation. BJU Int 97:634–639CrossRefPubMed
Sonier B, Lavigne C, Arseneault M, Ouellette R, Vaillancourt C (2005) Expression of the 5-HT2A serotoninergic receptor in human placenta and choriocarcinoma cells: mitogenic implications of serotonin. Placenta 26:484–490CrossRefPubMed
Sonier B, Arseneault M, Lavigne C, Ouellette RJ, Vaillancourt C (2006) The 5-HT2A serotoninergic receptor is expressed in the MCF-7 human breast cancer cell line and reveals a mitogenic effect of serotonin. Biochem Biophys Res Commun 343:1053–1059CrossRefPubMed
Tjomsland V, El-Salhy M (2005) Anti-tumour effects of triple therapy with octreotide, galanin and serotonin in comparison with those of 5-fluorouracil/leukovorin on human colon cancer. Int J Oncol 27:427–432PubMed
Weigent DA, Blalock JE (1995) Associations between the neuroendocrine and immune systems. J Leukoc Biol 58:137–150PubMed
Wilkinson LO, Dourish CT (1991) In: Peroutka SJ (ed) Serotonin receptor subtypes: basic and clinical aspects. Wiley, New York, pp 147–210
Xu W, Tamim H, Shapiro S, Stang MR, Collet JP (2006) Use of antidepressants and risk of colorectal cancer: a nested case–control study. Lancet Oncol 7:301–308CrossRefPubMed
Yue CT, Liu YL (2005) Fluoxetine increases extracellular levels of 3-methoxy-4-hydroxyphenylglycol in cultured COLO320 DM cells. Cell Biochem Funct 23:109–114CrossRefPubMed
Metadaten
Titel
Anti-mitogenic and apoptotic effects of 5-HT1B receptor antagonist on HT29 colorectal cancer cell line
verfasst von
Ramin Ataee
Soheila Ajdary
Mohammadreza Zarrindast
Mehdi Rezayat
Mohammad Reza Hayatbakhsh
Publikationsdatum
01.10.2010
Verlag
Springer-Verlag
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 10/2010
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-010-0801-3

Weitere Artikel der Ausgabe 10/2010

Journal of Cancer Research and Clinical Oncology 10/2010 Zur Ausgabe

Original Paper

The influence of TXNDC5 gene on gastric cancer cell

Original Paper

Expression and prognostic significance of focal adhesion kinase in hepatocellular carcinoma

Original Paper

Loss of SOCS3 expression is associated with an increased risk of recurrent disease in breast carcinoma

Original Paper

Induction of MKP-1 prevents the cytotoxic effects of PI3K inhibition in hilar cholangiocarcinoma cells

Original Paper

Perineural invasion in carcinoma of the cervix uteri—prognostic impact

Original Paper

Overexpression of Galectin-1 is negatively correlated with pathologic differentiation grade in oral squamous cell carcinoma

Neu im Fachgebiet Onkologie

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Bessere Prognose mit links- statt rechtsseitigem Kolon-Ca.

06.05.2024 Kolonkarzinom Nachrichten

Menschen mit linksseitigem Kolonkarzinom leben im Mittel zweieinhalb Jahre länger als solche mit rechtsseitigem Tumor. Auch aktuell ist das Sterberisiko bei linksseitigen Tumoren US-Daten zufolge etwa um 11% geringer als bei rechtsseitigen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise